CMR Surgical announces over 20,000 surgical cases completed using Versius
Over 20,000 surgical cases completed using Versius The versatile surgical robot Versius has now been used to perform over 20,000...
Year: 2024
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Achieves critical first step toward priority review voucherBASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq:...
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it...
BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024
Conference Call on Monday, April 1st, at 4:30 pm ETPOMPANO BEACH, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies...
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024On...
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21,...
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health...
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
Lead program in urea cycle disorders highlights power of CAMP4’s RAP Platform™ to increase gene expression using programmable, targeted medicines,...
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31,...
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
Figure 1 Dose escalation and subject numbers by dose since initiating the trial in March 2023 PYX-201 Phase 1 Part...
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Medical Review Committee approved initiation of recruitment of next cohort of patients, in alignment with dose optimization protocol First patient...
BrightSpring Health Services Recognizes its Valuable and Esteemed Female Leaders and Staff in Celebration of Women’s History Month
LOUISVILLE, Ky., March 21, 2024 (GLOBE NEWSWIRE) -- This Women’s History Month, BrightSpring Health Services, Inc. (“BrightSpring” or the “BrightSpring...
Therma Bright Announces Strategic Review & Update on Investment in Inretio
Toronto, Ontario--(Newsfile Corp. - March 21, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer...
Genflow Biosciences PLC Announces Notification of Major Holdings
LONDON, UK / ACCESSWIRE / March 21, 2024 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW...
Genflow Biosciences PLC Announces Publication of a Key European Patent
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET...
HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results
First Patients Enrolled in Pivotal Study Evaluating AIMIGo™ System for Synthesizing a 12-Lead ECG Ongoing Clinical and Regulatory Progress for...
Delivra Health Brands Announces Adoption of a New Fixed Share Option Plan
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or...
Avinger Reports Fourth Quarter and Full Year 2023 Results
New Strategic Partnership Provides Funding to Support U.S. Growth Initiatives and Coronary Product Development, Opens New Pathway for Sales in...
Music’s Healing Influence on Our Physiology
Pioneering the Path of Sound Therapy with Biofield TuningBURLINGTON, VERMONT / ACCESSWIRE / March 20, 2024 / The relentless pace...